GLP-1 Therapies: Evaluating Risks and Rewards Across Conditions

GLP‑1 receptor agonists have rapidly transformed the treatment landscape for type 2 diabetes and obesity—and their use is expanding far beyond their original indications. Once niche metabolic therapies, drugs such as semaglutide and tirzepatide are now among the most widely prescribed medicines worldwide.

This article explores how GLP‑1 therapies work, why their clinical potential extends across multiple conditions, and what has driven their unprecedented uptake. It examines both the therapeutic benefits and the safety considerations clinicians and patients must navigate, from common gastrointestinal side effects to rarer, more serious risks. The discussion also highlights the critical difference between relative and absolute risk, and why individualized assessment remains essential.

You’ll also gain insight into emerging next‑generation GLP‑1 strategies, including dual and triple agonists and novel delivery approaches designed to improve efficacy and tolerability.